cd125 Search Results


93
Miltenyi Biotec rea705
Antibodies used to characterize the neutrophil subpopulations.
Rea705, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rea705/product/Miltenyi Biotec
Average 93 stars, based on 1 article reviews
rea705 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

92
R&D Systems cd125
Antibodies used to characterize the neutrophil subpopulations.
Cd125, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd125/product/R&D Systems
Average 92 stars, based on 1 article reviews
cd125 - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier

93
Miltenyi Biotec human anti cd125 il5ra biotin validation
Antibodies used to characterize the neutrophil subpopulations.
Human Anti Cd125 Il5ra Biotin Validation, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human anti cd125 il5ra biotin validation/product/Miltenyi Biotec
Average 93 stars, based on 1 article reviews
human anti cd125 il5ra biotin validation - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

90
R&D Systems biotinylated goat anti human il 5r polyclonal ab
Antibodies used to characterize the neutrophil subpopulations.
Biotinylated Goat Anti Human Il 5r Polyclonal Ab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biotinylated goat anti human il 5r polyclonal ab/product/R&D Systems
Average 90 stars, based on 1 article reviews
biotinylated goat anti human il 5r polyclonal ab - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
R&D Systems anti il 5rα
Antibodies used to characterize the neutrophil subpopulations.
Anti Il 5rα, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti il 5rα/product/R&D Systems
Average 90 stars, based on 1 article reviews
anti il 5rα - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
R&D Systems anti human il5r polyclonal antibody
FIG. 1. Extracellular domain construct of <t>IL5R</t> used in biosensor analysis of mutational variants. A, comparison of soluble form of IL5R (lower) used in antibody-capture binding assay with full-length IL5R (upper) composed of an extracellular region (D1, D2, and D3), a transmembrane (TM) region and a cytoplasmic (CP) region. The soluble form of IL5R (sIL5R) corresponds to the extracellular region. V5-His tag was fused at the C-terminal region of D3 that normally adjoins the TM region. B, sequence alignment of extracellular regions of human and mouse IL5R, and rat prolactin receptor. Identical amino acid residues are marked by asterisks, and similar amino acid residues are marked by the “:” symbol. Multiple sequence alignments were performed by using PSI-BLAST (27) and ClustalW 1.60 (43), both of which provided similar results. Alignments were further adjusted manually (see “Experimental Procedures”). Groups of similar amino acid residues were categorized according to ClustalW 1.60. Underlines in the prolactin receptor sequence show the -strand regions determined by its crystal structure (26). An alignment of the human growth hormone and human IL5R was initially used to design the position of mutagenesis, whereas crystal structure of rat prolactin receptor was used for homology modeling. The -strand regions estimated from human growth hormone and rat prolactin receptor were essentially the same, except for the -strand G in D2 domain. Shaded are the residues that were substituted by alanine in this study.
Anti Human Il5r Polyclonal Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti human il5r polyclonal antibody/product/R&D Systems
Average 90 stars, based on 1 article reviews
anti human il5r polyclonal antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

91
Bioss p stat5
Gαi1/3 knockdown inhibits <t>STAT5</t> activation, differentiation and growth by IL-5 in EoL-1 cells. Stable EoL-1 cells, expressing the scramble control shRNA (“C-shRNA”), Gαi1 shRNA and Gαi3 shRNA, were treated with GM-CSF (50 ng/mL) and IL-5 (50 ng/mL) for 24 hours, and were tested by Western blotting of listed proteins (A, E) . Relative expression of listed genes (24 hours after GM-CSF and IL-5 treatment) was shown (B, C) ; In each experiment, n=3 (three replicated wells). Cells were further cultured for the times indicated, cell proliferation were tested (F, G) , with cell viability tested by CCK-8 assay (D) . Bar = 100 μm. Blotting quantification was performed from five replicate blot data, data of all repeated experiments were pulled together to calculate mean ± SD. *P <0.05 (B, E, G) . *P <0.05 vs. “Control” treatment in “C-shRNA” EoL-1 cells (C) . # P <0.05 vs. GM-CSF and IL-5 treatment in “C-shRNA” EoL-1 cells (C) . *P <0.05 vs. “Control” treatment in “Gαi1/3-shRNA” EoL-1 cells (D) . #P <0.05 vs. GM-CSF and IL-5 treatment in “Gαi1/3-shRNA” EoL-1 cells (D) .
P Stat5, supplied by Bioss, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p stat5/product/Bioss
Average 91 stars, based on 1 article reviews
p stat5 - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier

93
Miltenyi Biotec anti cd125 il 5rα apc
Gαi1/3 knockdown inhibits <t>STAT5</t> activation, differentiation and growth by IL-5 in EoL-1 cells. Stable EoL-1 cells, expressing the scramble control shRNA (“C-shRNA”), Gαi1 shRNA and Gαi3 shRNA, were treated with GM-CSF (50 ng/mL) and IL-5 (50 ng/mL) for 24 hours, and were tested by Western blotting of listed proteins (A, E) . Relative expression of listed genes (24 hours after GM-CSF and IL-5 treatment) was shown (B, C) ; In each experiment, n=3 (three replicated wells). Cells were further cultured for the times indicated, cell proliferation were tested (F, G) , with cell viability tested by CCK-8 assay (D) . Bar = 100 μm. Blotting quantification was performed from five replicate blot data, data of all repeated experiments were pulled together to calculate mean ± SD. *P <0.05 (B, E, G) . *P <0.05 vs. “Control” treatment in “C-shRNA” EoL-1 cells (C) . # P <0.05 vs. GM-CSF and IL-5 treatment in “C-shRNA” EoL-1 cells (C) . *P <0.05 vs. “Control” treatment in “Gαi1/3-shRNA” EoL-1 cells (D) . #P <0.05 vs. GM-CSF and IL-5 treatment in “Gαi1/3-shRNA” EoL-1 cells (D) .
Anti Cd125 Il 5rα Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd125 il 5rα apc/product/Miltenyi Biotec
Average 93 stars, based on 1 article reviews
anti cd125 il 5rα apc - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

91
R&D Systems il5 ra
Gαi1/3 knockdown inhibits <t>STAT5</t> activation, differentiation and growth by IL-5 in EoL-1 cells. Stable EoL-1 cells, expressing the scramble control shRNA (“C-shRNA”), Gαi1 shRNA and Gαi3 shRNA, were treated with GM-CSF (50 ng/mL) and IL-5 (50 ng/mL) for 24 hours, and were tested by Western blotting of listed proteins (A, E) . Relative expression of listed genes (24 hours after GM-CSF and IL-5 treatment) was shown (B, C) ; In each experiment, n=3 (three replicated wells). Cells were further cultured for the times indicated, cell proliferation were tested (F, G) , with cell viability tested by CCK-8 assay (D) . Bar = 100 μm. Blotting quantification was performed from five replicate blot data, data of all repeated experiments were pulled together to calculate mean ± SD. *P <0.05 (B, E, G) . *P <0.05 vs. “Control” treatment in “C-shRNA” EoL-1 cells (C) . # P <0.05 vs. GM-CSF and IL-5 treatment in “C-shRNA” EoL-1 cells (C) . *P <0.05 vs. “Control” treatment in “Gαi1/3-shRNA” EoL-1 cells (D) . #P <0.05 vs. GM-CSF and IL-5 treatment in “Gαi1/3-shRNA” EoL-1 cells (D) .
Il5 Ra, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il5 ra/product/R&D Systems
Average 91 stars, based on 1 article reviews
il5 ra - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier

93
Miltenyi Biotec il5r
Gαi1/3 knockdown inhibits <t>STAT5</t> activation, differentiation and growth by IL-5 in EoL-1 cells. Stable EoL-1 cells, expressing the scramble control shRNA (“C-shRNA”), Gαi1 shRNA and Gαi3 shRNA, were treated with GM-CSF (50 ng/mL) and IL-5 (50 ng/mL) for 24 hours, and were tested by Western blotting of listed proteins (A, E) . Relative expression of listed genes (24 hours after GM-CSF and IL-5 treatment) was shown (B, C) ; In each experiment, n=3 (three replicated wells). Cells were further cultured for the times indicated, cell proliferation were tested (F, G) , with cell viability tested by CCK-8 assay (D) . Bar = 100 μm. Blotting quantification was performed from five replicate blot data, data of all repeated experiments were pulled together to calculate mean ± SD. *P <0.05 (B, E, G) . *P <0.05 vs. “Control” treatment in “C-shRNA” EoL-1 cells (C) . # P <0.05 vs. GM-CSF and IL-5 treatment in “C-shRNA” EoL-1 cells (C) . *P <0.05 vs. “Control” treatment in “Gαi1/3-shRNA” EoL-1 cells (D) . #P <0.05 vs. GM-CSF and IL-5 treatment in “Gαi1/3-shRNA” EoL-1 cells (D) .
Il5r, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il5r/product/Miltenyi Biotec
Average 93 stars, based on 1 article reviews
il5r - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

93
Proteintech anti il5ra antibodies
Gαi1/3 knockdown inhibits <t>STAT5</t> activation, differentiation and growth by IL-5 in EoL-1 cells. Stable EoL-1 cells, expressing the scramble control shRNA (“C-shRNA”), Gαi1 shRNA and Gαi3 shRNA, were treated with GM-CSF (50 ng/mL) and IL-5 (50 ng/mL) for 24 hours, and were tested by Western blotting of listed proteins (A, E) . Relative expression of listed genes (24 hours after GM-CSF and IL-5 treatment) was shown (B, C) ; In each experiment, n=3 (three replicated wells). Cells were further cultured for the times indicated, cell proliferation were tested (F, G) , with cell viability tested by CCK-8 assay (D) . Bar = 100 μm. Blotting quantification was performed from five replicate blot data, data of all repeated experiments were pulled together to calculate mean ± SD. *P <0.05 (B, E, G) . *P <0.05 vs. “Control” treatment in “C-shRNA” EoL-1 cells (C) . # P <0.05 vs. GM-CSF and IL-5 treatment in “C-shRNA” EoL-1 cells (C) . *P <0.05 vs. “Control” treatment in “Gαi1/3-shRNA” EoL-1 cells (D) . #P <0.05 vs. GM-CSF and IL-5 treatment in “Gαi1/3-shRNA” EoL-1 cells (D) .
Anti Il5ra Antibodies, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti il5ra antibodies/product/Proteintech
Average 93 stars, based on 1 article reviews
anti il5ra antibodies - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

90
Becton Dickinson pe anti-cd125 (a14
Gαi1/3 knockdown inhibits <t>STAT5</t> activation, differentiation and growth by IL-5 in EoL-1 cells. Stable EoL-1 cells, expressing the scramble control shRNA (“C-shRNA”), Gαi1 shRNA and Gαi3 shRNA, were treated with GM-CSF (50 ng/mL) and IL-5 (50 ng/mL) for 24 hours, and were tested by Western blotting of listed proteins (A, E) . Relative expression of listed genes (24 hours after GM-CSF and IL-5 treatment) was shown (B, C) ; In each experiment, n=3 (three replicated wells). Cells were further cultured for the times indicated, cell proliferation were tested (F, G) , with cell viability tested by CCK-8 assay (D) . Bar = 100 μm. Blotting quantification was performed from five replicate blot data, data of all repeated experiments were pulled together to calculate mean ± SD. *P <0.05 (B, E, G) . *P <0.05 vs. “Control” treatment in “C-shRNA” EoL-1 cells (C) . # P <0.05 vs. GM-CSF and IL-5 treatment in “C-shRNA” EoL-1 cells (C) . *P <0.05 vs. “Control” treatment in “Gαi1/3-shRNA” EoL-1 cells (D) . #P <0.05 vs. GM-CSF and IL-5 treatment in “Gαi1/3-shRNA” EoL-1 cells (D) .
Pe Anti Cd125 (A14, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pe anti-cd125 (a14/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
pe anti-cd125 (a14 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Antibodies used to characterize the neutrophil subpopulations.

Journal: Frontiers in Immunology

Article Title: Local Innate Markers and Vaginal Microbiota Composition Are Influenced by Hormonal Cycle Phases

doi: 10.3389/fimmu.2022.841723

Figure Lengend Snippet: Antibodies used to characterize the neutrophil subpopulations.

Article Snippet: CDw125 , REA705 , PE , 2.5 μL , 130-110-544 , Milteny.

Techniques: Clone Assay, Concentration Assay

FIG. 1. Extracellular domain construct of IL5R used in biosensor analysis of mutational variants. A, comparison of soluble form of IL5R (lower) used in antibody-capture binding assay with full-length IL5R (upper) composed of an extracellular region (D1, D2, and D3), a transmembrane (TM) region and a cytoplasmic (CP) region. The soluble form of IL5R (sIL5R) corresponds to the extracellular region. V5-His tag was fused at the C-terminal region of D3 that normally adjoins the TM region. B, sequence alignment of extracellular regions of human and mouse IL5R, and rat prolactin receptor. Identical amino acid residues are marked by asterisks, and similar amino acid residues are marked by the “:” symbol. Multiple sequence alignments were performed by using PSI-BLAST (27) and ClustalW 1.60 (43), both of which provided similar results. Alignments were further adjusted manually (see “Experimental Procedures”). Groups of similar amino acid residues were categorized according to ClustalW 1.60. Underlines in the prolactin receptor sequence show the -strand regions determined by its crystal structure (26). An alignment of the human growth hormone and human IL5R was initially used to design the position of mutagenesis, whereas crystal structure of rat prolactin receptor was used for homology modeling. The -strand regions estimated from human growth hormone and rat prolactin receptor were essentially the same, except for the -strand G in D2 domain. Shaded are the residues that were substituted by alanine in this study.

Journal: Journal of Biological Chemistry

Article Title: Kinetic Interaction Analysis of Human Interleukin 5 Receptor α Mutants Reveals a Unique Binding Topology and Charge Distribution for Cytokine Recognition

doi: 10.1074/jbc.m309327200

Figure Lengend Snippet: FIG. 1. Extracellular domain construct of IL5R used in biosensor analysis of mutational variants. A, comparison of soluble form of IL5R (lower) used in antibody-capture binding assay with full-length IL5R (upper) composed of an extracellular region (D1, D2, and D3), a transmembrane (TM) region and a cytoplasmic (CP) region. The soluble form of IL5R (sIL5R) corresponds to the extracellular region. V5-His tag was fused at the C-terminal region of D3 that normally adjoins the TM region. B, sequence alignment of extracellular regions of human and mouse IL5R, and rat prolactin receptor. Identical amino acid residues are marked by asterisks, and similar amino acid residues are marked by the “:” symbol. Multiple sequence alignments were performed by using PSI-BLAST (27) and ClustalW 1.60 (43), both of which provided similar results. Alignments were further adjusted manually (see “Experimental Procedures”). Groups of similar amino acid residues were categorized according to ClustalW 1.60. Underlines in the prolactin receptor sequence show the -strand regions determined by its crystal structure (26). An alignment of the human growth hormone and human IL5R was initially used to design the position of mutagenesis, whereas crystal structure of rat prolactin receptor was used for homology modeling. The -strand regions estimated from human growth hormone and rat prolactin receptor were essentially the same, except for the -strand G in D2 domain. Shaded are the residues that were substituted by alanine in this study.

Article Snippet: Levels of expression were measured for both cell cultures and precipitants by Western blot using anti-human IL5R polyclonal antibody (R&D Systems) and anti-histidine tag polyclonal antibody (Santa Cruz Biotechnology).

Techniques: Construct, Comparison, Binding Assay, Sequencing, Mutagenesis

FIG. 2. Basic features and Ramachandran plot of modeled structure of sIL5R. A, homology model of the tertiary structure of the extracellular region of IL5R. Loops are represented as coils and -strands as ribbons. In this structure, each fibronectin type III domain of IL5R is termed D1, D2, and D3 from the N to the C termini, which are labeled N-ter and C-ter, respectively. D2 and D3 domains have sequence homology with the classic cytokine recognition motif (CRM). Seven cysteine residues are shown as CPK (Corey Pauling Kultin) models and labeled by residue type and number. One disulfide bond (Cys114-Cys135) links the neighboring strands A and B and another disulfide bond (Cys162-Cys176) links strands D and E. In this modeled structure, a disulfide bond between Cys249 and Cys296 in D3 domain was introduced (see “Experimental Procedures”). The guanidinium group of Arg290 was intercalated between the two indole rings from the WSXWS motif in D3 domain. The tryptophan residues are shown as CPK mod- els, and the arginine residue is shown as a ball-and-stick model. All the molecular graphic figures in this article were prepared with the pro- gram MOLMOL (42). B, the Ramachandran plot analysis by PRO- CHECK (30) showed that 85.5% of non-glycine and non-proline residues fell into the most favored regions, 12.4% into the additional allowed regions, 2.1% into the generously allowed regions, and no non-glycine residues in disallowed regions.

Journal: Journal of Biological Chemistry

Article Title: Kinetic Interaction Analysis of Human Interleukin 5 Receptor α Mutants Reveals a Unique Binding Topology and Charge Distribution for Cytokine Recognition

doi: 10.1074/jbc.m309327200

Figure Lengend Snippet: FIG. 2. Basic features and Ramachandran plot of modeled structure of sIL5R. A, homology model of the tertiary structure of the extracellular region of IL5R. Loops are represented as coils and -strands as ribbons. In this structure, each fibronectin type III domain of IL5R is termed D1, D2, and D3 from the N to the C termini, which are labeled N-ter and C-ter, respectively. D2 and D3 domains have sequence homology with the classic cytokine recognition motif (CRM). Seven cysteine residues are shown as CPK (Corey Pauling Kultin) models and labeled by residue type and number. One disulfide bond (Cys114-Cys135) links the neighboring strands A and B and another disulfide bond (Cys162-Cys176) links strands D and E. In this modeled structure, a disulfide bond between Cys249 and Cys296 in D3 domain was introduced (see “Experimental Procedures”). The guanidinium group of Arg290 was intercalated between the two indole rings from the WSXWS motif in D3 domain. The tryptophan residues are shown as CPK mod- els, and the arginine residue is shown as a ball-and-stick model. All the molecular graphic figures in this article were prepared with the pro- gram MOLMOL (42). B, the Ramachandran plot analysis by PRO- CHECK (30) showed that 85.5% of non-glycine and non-proline residues fell into the most favored regions, 12.4% into the additional allowed regions, 2.1% into the generously allowed regions, and no non-glycine residues in disallowed regions.

Article Snippet: Levels of expression were measured for both cell cultures and precipitants by Western blot using anti-human IL5R polyclonal antibody (R&D Systems) and anti-histidine tag polyclonal antibody (Santa Cruz Biotechnology).

Techniques: Labeling, Sequencing, Residue

FIG. 3. Western blotting of sIL5R variants. A, Western blotting of secreted wild type sIL5R. Lane 1 shows the band stained by anti- human IL5R polyclonal antibody; lane 2, the band stained by anti- histidine tag polyclonal antibody. B, Western blotting of the superna- tants (upper) and precipitates (lower) of non-secretion variants by anti- histidine tag polyclonal antibody: lane 1, positive control (wild type IL5R); lane 2, negative control (empty vector transfection); lane 3, H71A; lane 4, K167A/D168A; lane 5, R172A; lane 6, D189A; lane 7, R260A; and lane 8, D279A/D280A.

Journal: Journal of Biological Chemistry

Article Title: Kinetic Interaction Analysis of Human Interleukin 5 Receptor α Mutants Reveals a Unique Binding Topology and Charge Distribution for Cytokine Recognition

doi: 10.1074/jbc.m309327200

Figure Lengend Snippet: FIG. 3. Western blotting of sIL5R variants. A, Western blotting of secreted wild type sIL5R. Lane 1 shows the band stained by anti- human IL5R polyclonal antibody; lane 2, the band stained by anti- histidine tag polyclonal antibody. B, Western blotting of the superna- tants (upper) and precipitates (lower) of non-secretion variants by anti- histidine tag polyclonal antibody: lane 1, positive control (wild type IL5R); lane 2, negative control (empty vector transfection); lane 3, H71A; lane 4, K167A/D168A; lane 5, R172A; lane 6, D189A; lane 7, R260A; and lane 8, D279A/D280A.

Article Snippet: Levels of expression were measured for both cell cultures and precipitants by Western blot using anti-human IL5R polyclonal antibody (R&D Systems) and anti-histidine tag polyclonal antibody (Santa Cruz Biotechnology).

Techniques: Western Blot, Staining, Positive Control, Negative Control, Plasmid Preparation, Transfection

FIG. 4. Epitope analysis and mapping for a non-neutralizing anti human IL5R antibody 16. A, Biacore-derived real-time sen- sorgrams of the interactions of wild type IL5R and receptor variants, which impaired the high affinity interaction with 16. Receptor sam- ples were injected onto the immobilized 16 surface at zero time, and arrows shows the time when the injections reverted to buffer alone. B, mapping of the 16 epitope on the modeled structures of IL5R. Resi- dues that impaired, through alanine substitution, the high affinity interaction with 16 are shown as CPK models and labeled by residue type and number. Residues that caused non-secretion through alanine substitutions (Table II) are shown as ball-and-stick models.

Journal: Journal of Biological Chemistry

Article Title: Kinetic Interaction Analysis of Human Interleukin 5 Receptor α Mutants Reveals a Unique Binding Topology and Charge Distribution for Cytokine Recognition

doi: 10.1074/jbc.m309327200

Figure Lengend Snippet: FIG. 4. Epitope analysis and mapping for a non-neutralizing anti human IL5R antibody 16. A, Biacore-derived real-time sen- sorgrams of the interactions of wild type IL5R and receptor variants, which impaired the high affinity interaction with 16. Receptor sam- ples were injected onto the immobilized 16 surface at zero time, and arrows shows the time when the injections reverted to buffer alone. B, mapping of the 16 epitope on the modeled structures of IL5R. Resi- dues that impaired, through alanine substitution, the high affinity interaction with 16 are shown as CPK models and labeled by residue type and number. Residues that caused non-secretion through alanine substitutions (Table II) are shown as ball-and-stick models.

Article Snippet: Levels of expression were measured for both cell cultures and precipitants by Western blot using anti-human IL5R polyclonal antibody (R&D Systems) and anti-histidine tag polyclonal antibody (Santa Cruz Biotechnology).

Techniques: Derivative Assay, Injection, Labeling, Residue

FIG. 5. Biosensor binding analysis of sIL5R. A, anti-V5 tag monoclonal an- tibody was covalently immobilized to the dextran matrix on a sensor chip gold sur- face. sIL5R was captured on the surface via tight interaction of V5 tag and the antibody, providing the similar configura- tion to cell surface receptors. IL5 was then injected to the sIL5R-captured sur- face, and its kinetic interaction was exam- ined. B, the effect of flow rate. The asso- ciation rates were measured at flow rates of 10, 20, 40, or 80 l/min (cyan, blue, green, or red, respectively). C, overlay of real-time sensorgrams shows sequential injections of cell-free media containing sIL5R (a), injection of running buffer (b), injections of 0, 12.5, 25, and 50 nM of IL5 (c), injection of running buffer alone (d), and injections of the regeneration buffer (e). D, global fitting of wild type IL5R. Various concentrations of IL5 (0, 12.5, 25, and 50 nM) were injected. The rate con- stants were calculated by fitting the asso- ciation phase and dissociation phase to a model for 1:1 Langmuir binding with mass transfer. Residuals are shown in the lower panel of D. Magenta dots show ex- perimental sensorgrams, and black lines show calculated sensorgrams.

Journal: Journal of Biological Chemistry

Article Title: Kinetic Interaction Analysis of Human Interleukin 5 Receptor α Mutants Reveals a Unique Binding Topology and Charge Distribution for Cytokine Recognition

doi: 10.1074/jbc.m309327200

Figure Lengend Snippet: FIG. 5. Biosensor binding analysis of sIL5R. A, anti-V5 tag monoclonal an- tibody was covalently immobilized to the dextran matrix on a sensor chip gold sur- face. sIL5R was captured on the surface via tight interaction of V5 tag and the antibody, providing the similar configura- tion to cell surface receptors. IL5 was then injected to the sIL5R-captured sur- face, and its kinetic interaction was exam- ined. B, the effect of flow rate. The asso- ciation rates were measured at flow rates of 10, 20, 40, or 80 l/min (cyan, blue, green, or red, respectively). C, overlay of real-time sensorgrams shows sequential injections of cell-free media containing sIL5R (a), injection of running buffer (b), injections of 0, 12.5, 25, and 50 nM of IL5 (c), injection of running buffer alone (d), and injections of the regeneration buffer (e). D, global fitting of wild type IL5R. Various concentrations of IL5 (0, 12.5, 25, and 50 nM) were injected. The rate con- stants were calculated by fitting the asso- ciation phase and dissociation phase to a model for 1:1 Langmuir binding with mass transfer. Residuals are shown in the lower panel of D. Magenta dots show ex- perimental sensorgrams, and black lines show calculated sensorgrams.

Article Snippet: Levels of expression were measured for both cell cultures and precipitants by Western blot using anti-human IL5R polyclonal antibody (R&D Systems) and anti-histidine tag polyclonal antibody (Santa Cruz Biotechnology).

Techniques: Binding Assay, Injection

FIG. 6. Mutations that diminished the high affinity interaction of IL5R with IL5. Binding curves of (A) the D1 mutants and (B) the D2D3 mutants, which markedly decreased the binding af- finity. Each sensorgram shows the associ- ation (0–60 s) and dissociation (60–180 s) of IL5 (50 nM) to sIL5R or the mutational variants captured by anti-V5 tag anti- body. For comparison, sensorgrams were normalized depending on the amount of captured protein. Various concentrations of IL5 (0, 50, 100, and 250 nM) were in- jected to captured D55A variant (C) or R188A variant (D). The interaction curves were globally fit using Langmuir 1:1 bind- ing with mass transfer. Residuals are shown in the lower panels in C and D. Magenta dots show experimental sensor- grams, and black lines show calculated sensorgrams.

Journal: Journal of Biological Chemistry

Article Title: Kinetic Interaction Analysis of Human Interleukin 5 Receptor α Mutants Reveals a Unique Binding Topology and Charge Distribution for Cytokine Recognition

doi: 10.1074/jbc.m309327200

Figure Lengend Snippet: FIG. 6. Mutations that diminished the high affinity interaction of IL5R with IL5. Binding curves of (A) the D1 mutants and (B) the D2D3 mutants, which markedly decreased the binding af- finity. Each sensorgram shows the associ- ation (0–60 s) and dissociation (60–180 s) of IL5 (50 nM) to sIL5R or the mutational variants captured by anti-V5 tag anti- body. For comparison, sensorgrams were normalized depending on the amount of captured protein. Various concentrations of IL5 (0, 50, 100, and 250 nM) were in- jected to captured D55A variant (C) or R188A variant (D). The interaction curves were globally fit using Langmuir 1:1 bind- ing with mass transfer. Residuals are shown in the lower panels in C and D. Magenta dots show experimental sensor- grams, and black lines show calculated sensorgrams.

Article Snippet: Levels of expression were measured for both cell cultures and precipitants by Western blot using anti-human IL5R polyclonal antibody (R&D Systems) and anti-histidine tag polyclonal antibody (Santa Cruz Biotechnology).

Techniques: Binding Assay, Comparison, Variant Assay

FIG. 7. Hypothetical structure of the IL5 complex with IL5R. Both IL5 (R91 and E110) and IL5R (D55, D56, E58, K186, R188, and R297) epitope residues are expressed in the CPK model.

Journal: Journal of Biological Chemistry

Article Title: Kinetic Interaction Analysis of Human Interleukin 5 Receptor α Mutants Reveals a Unique Binding Topology and Charge Distribution for Cytokine Recognition

doi: 10.1074/jbc.m309327200

Figure Lengend Snippet: FIG. 7. Hypothetical structure of the IL5 complex with IL5R. Both IL5 (R91 and E110) and IL5R (D55, D56, E58, K186, R188, and R297) epitope residues are expressed in the CPK model.

Article Snippet: Levels of expression were measured for both cell cultures and precipitants by Western blot using anti-human IL5R polyclonal antibody (R&D Systems) and anti-histidine tag polyclonal antibody (Santa Cruz Biotechnology).

Techniques:

Gαi1/3 knockdown inhibits STAT5 activation, differentiation and growth by IL-5 in EoL-1 cells. Stable EoL-1 cells, expressing the scramble control shRNA (“C-shRNA”), Gαi1 shRNA and Gαi3 shRNA, were treated with GM-CSF (50 ng/mL) and IL-5 (50 ng/mL) for 24 hours, and were tested by Western blotting of listed proteins (A, E) . Relative expression of listed genes (24 hours after GM-CSF and IL-5 treatment) was shown (B, C) ; In each experiment, n=3 (three replicated wells). Cells were further cultured for the times indicated, cell proliferation were tested (F, G) , with cell viability tested by CCK-8 assay (D) . Bar = 100 μm. Blotting quantification was performed from five replicate blot data, data of all repeated experiments were pulled together to calculate mean ± SD. *P <0.05 (B, E, G) . *P <0.05 vs. “Control” treatment in “C-shRNA” EoL-1 cells (C) . # P <0.05 vs. GM-CSF and IL-5 treatment in “C-shRNA” EoL-1 cells (C) . *P <0.05 vs. “Control” treatment in “Gαi1/3-shRNA” EoL-1 cells (D) . #P <0.05 vs. GM-CSF and IL-5 treatment in “Gαi1/3-shRNA” EoL-1 cells (D) .

Journal: Frontiers in Immunology

Article Title: Gαi1/3 signaling mediates IL-5-induced eosinophil activation and type 2 inflammation in eosinophilic chronic rhinosinusitis

doi: 10.3389/fimmu.2024.1460104

Figure Lengend Snippet: Gαi1/3 knockdown inhibits STAT5 activation, differentiation and growth by IL-5 in EoL-1 cells. Stable EoL-1 cells, expressing the scramble control shRNA (“C-shRNA”), Gαi1 shRNA and Gαi3 shRNA, were treated with GM-CSF (50 ng/mL) and IL-5 (50 ng/mL) for 24 hours, and were tested by Western blotting of listed proteins (A, E) . Relative expression of listed genes (24 hours after GM-CSF and IL-5 treatment) was shown (B, C) ; In each experiment, n=3 (three replicated wells). Cells were further cultured for the times indicated, cell proliferation were tested (F, G) , with cell viability tested by CCK-8 assay (D) . Bar = 100 μm. Blotting quantification was performed from five replicate blot data, data of all repeated experiments were pulled together to calculate mean ± SD. *P <0.05 (B, E, G) . *P <0.05 vs. “Control” treatment in “C-shRNA” EoL-1 cells (C) . # P <0.05 vs. GM-CSF and IL-5 treatment in “C-shRNA” EoL-1 cells (C) . *P <0.05 vs. “Control” treatment in “Gαi1/3-shRNA” EoL-1 cells (D) . #P <0.05 vs. GM-CSF and IL-5 treatment in “Gαi1/3-shRNA” EoL-1 cells (D) .

Article Snippet: Antibodies against Gαi1 (sc-13533), Gαi2 (sc-13534), Gαi3 (sc-365422), Gab1 (sc-133191), Akt (sc-81434), Erk1/2 (sc-514302), S6K (sc-8418), p-Gab1 (AP0256), p-Akt s473 (sc-101629), p-Erk1/2 (sc-136521), p-S6K (sc-8416), STAT5 (sc-74442), p-STAT5 (AP-0887), IL-5Rα (bs-2601R-100ul), IgE (ab75673), and tryptase (ab2378) were purchased from Bioss (Woburn, MA, USA), ABcolnal (Wuhan, China), Abcam (Cambridge, MA, USA), and Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Techniques: Knockdown, Activation Assay, Expressing, Control, shRNA, Western Blot, Cell Culture, CCK-8 Assay